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Objective—To determine the rates of and risk factors for tigecycline non-susceptibility among 
carbapenem-resistant Klebsiella pneumoniae (CRKP) isolated from hospitalized patients.
Design—Multicenter prospective observational study
Setting—Acute care hospitals participating in the Consortium on Resistance against 
Carbapenems in Klebsiella pneumoniae (CRaCKle)
Patients—287 patients who had CRKP isolated from clinical cultures during hospitalization
Methods—Within the study period of 12/24/2011 – 10/1/2013, the first hospitalization of each 
patient with CRKP was included during which tigecycline susceptibility for the CRKP isolate was 
determined. Clinical data was entered into a centralized database, including data on pre-hospital 
origin. Breakpoints established by the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) were used to interpret tigecycline susceptibility testing.
Results—Of 287 patients included, 155 (54%) had tigecycline-susceptible CRKP, whereas 81 
(28%) of index isolates were tigecycline-intermediate, and 51 (18%) were tigecycline-resistant. In 
multivariable modeling, admission from a skilled nursing facility (OR 2.51, 95% CI 1.51–4.21, 
p=0.0004), positive culture within 2 days of admission (OR 1.82, 95% CI 1.06–3.15, p=0.03), and 
receipt of tigecycline within 14 days (OR 4.38, 95% CI 1.37–17.01, p=0.02) were found to be 
independent risk factors for tigecycline non-susceptibility.
Conclusions—In hospitalized patients with CRKP, tigecycline non-susceptibility was more 
frequently seen in admissions from skilled nursing facilities and occurred earlier during 
hospitalization. Skilled nursing facilities are an important target for interventions to decrease 
antibacterial resistance to antibiotics of last resort for treatment of CRKP.
Introduction
The rise of carbapenem resistance in Enterobacteriaceae poses a global threat to the 
accomplishments of modern medicine1,2. Advances in transplant medicine, surgery, and 
oncology are specifically at risk. The current treatment options for infections due to 
carbapenem resistant Enterobacteriaceae (CRE) are very limited as most isolates are 
resistant to multiple classes of antibiotics. Antibacterials of last resort which are being used 
in the treatment of CRE include aminoglycosides, polymyxins, fosfomycin and tigecycline3. 
Novel antibiotics with activity against CRE are currently under study including the 
aminoglycoside plazomicin, and novel β-lactam/β-lactamase inhibitors such as ceftazidime/
avibactam4,5. These compounds hold promise for more efficacious treatment of CRE 
infections combined with a more favorable side effect profile. However, development of 
resistance remains a concern for all current and future antibiotics as resistance may spread 
rapidly amongst Enterobacteriaceae through plasmids and other mobile genetic elements6.
Causes of resistance development to various antibiotics are likely to overlap. Therefore, 
variables associated with tigecycline resistance, which has been increasingly observed in 
CRE isolates, may inform strategies to limit development of resistance against newer agents. 
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In this context, we decided to study variables associated with tigecycline resistance in the 
Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRaCKle).
METHODS
Patients
The current study represents a nested cohort within Consortium on Resistance against 
Carbapenems in Klebsiella pneumoniae (CRaCKle) study, that was previously described7,8. 
Briefly, CRaCKle is a prospective, observational, multicenter study which aims to study 
patients who have positive cultures for CRKP during their hospitalization. This nested 
cohort consists of all hospitalized patients who had a clinical culture which grew CRKP 
during their hospitalization that was tested for tigecycline susceptibility. Patients were 
included if their index hospitalization began and ended in the study period 12/24/2011 – 
10/1/2013. Patients were included once at the time of their first positive culture. Patients 
who were known to be colonized with CRKP were placed in contact isolation. The 
Institutional Review Boards of all health systems involved approved the study.
Microbiology
CRKP are defined as K. pneumoniae isolates with non-susceptibility to the following 
carbapenems as per Clinical and Laboratory Standards Institute (CLSI) guidelines; 
meropenem, imipenem or ertapenem9. Bacterial identification and routine antimicrobial 
susceptibility testing was performed with MicroScan (Siemens Healthcare Diagnostics) or 
Vitek2 (BioMerieux), supplemented by GN4F Sensititre tray (Thermo Fisher) to confirm 
carbapenem results and to test tigecycline susceptibility. The majority of CRKP in CRaCKle 
are confirmed to carry blaKPC, as previously described8. For interpretation of tigecycline 
MIC results breakpoints defined by the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) were used; susceptible, intermediate, and resistant defined 
as MIC <2 μg/mL, 2 μg/mL, and >2 μg/mL, respectively.
Clinical Data
Clinical data was obtained from the electronic medical record, and entered into a centralized 
database. The index hospitalization was designated as the first hospital stay within the study 
period during which CRKP was isolated when the CRKP isolate was tested for tigecycline 
susceptibility. Standardized criteria for CRKP infection were used, as previously described8. 
Briefly, CR-Kp was isolated from blood or any other sterile source represented infection. 
For patients with positive respiratory cultures the criteria outlined by the American Thoracic 
Society (ATS) and the Infectious Diseases Society of America (IDSA) were used10,11. For 
patients with positive cultures from urine or surgical wounds, the CDC/NHSN criteria were 
used12. Critical illness was defined as a Pitt bacteremia score greater or equal to 4 points, on 
the day of the index culture13. Charlson comorbidity index was calculated14. The onset was 
considered present on admission (POA) if the first positive culture for CRKP was obtained 
within 48 hours of hospitalization.
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Differences between groups were analyzed using Wilcoxon Rank Sum for continuous 
variables. Fisher’s Exact, and Pearson testing were used for categorical variables where 
appropriate. A multivariable logistic regression model was constructed including all pre-
culture variables that were associated with tigecycline non-susceptibility at the level of 
p<0.1 in univariate analysis. In addition, a multivariable ordinal logistic model was 
constructed to test associations with the ordinal outcome of tigecycline susceptibility 
(susceptible vs. intermediate vs. resistant). Analyses were performed using JMP software 
(SAS Inc, Cary, NC).
Results
Patients
During the study period, 287 patients were included. Their demographics are listed in Table 
1. In this nested cohort, patients tended to be elderly with a median age of 71 years 
(interquartile range [IQR] 59–81 years), 63% of patients were female, and 54% were white. 
Comorbidities were common; the median Charlson comorbidity index was 3 (IQR 2–5), and 
more than half of patients had diabetes mellitus. The majority of patients were admitted 
from skilled nursing facilities (SNF) (53%), but 27% were admitted from home.
Cultures and timing of onset
Culture data are summarized in Table 2. Urine (61%) was by far the most common anatomic 
source for positive CRKP cultures. Only 44/175 (25%) of urine cultures represented a UTI. 
Overall, 44% of all patients met criteria for CRKP infection. Critical illness was present in 
32% of patients. Critical illness at the time of first positive culture was more common in 
patients with CRKP infection as compared to CRKP colonization; 56/127 (44%) of patients 
with infection were critically ill, as compared to 37/123 (23%) of patients with colonization 
(p=0.0002). Overall length of hospital stay was prolonged at a median of 10 days (IQR 6–18 
days). Remarkably, most of this hospital stay took place after the first positive CRKP 
culture. The median time from admission to first positive CRKP was one day (IQR 0–5 
days). In 184 (64%) of patients CRKP was deemed POA. In multivariable analysis, SNF 
origin, anatomic source, and critical illness were associated with CRKP that were POA. 
POA onset was more common in patients admitted from a SNF. POA onset was noted in 
112/153 (73%) patients admitted from SNF vs. in 72/134 (54%) patients admitted from 
other venues (OR 2.53, 95%CI 1.49–4.35, p=0.0006). Using respiratory source (26%) as a 
reference, POA onset was noted for 73%, 64%, 59%, 44% of patients with urine (OR 6.07, 
95%CI 2.50–16.00), wound (OR 3.84, 95%CI 1.29–12.28), blood (OR 4.36, 95%CI 1.54–
13.30), other (OR 2.24, 95%CI 0.43–11.33) anatomic sources, respectively (p=0.0014). In 
patients with critical illness, POA onset was less common; 48% vs. 72% in patients without 
critical illness at the time of first CRKP positive culture (OR 0.43 95%CI 0.24–0.76, 
p=0.004).
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Antibiotics used in the 14-day period preceding the first positive CRKP culture are outlined 
in Table 3. In the cohort as a whole, 39% of patients received at least one antibiotic in that 
period. The most common antibiotic used was vancomycin, which was administered to 30% 
of patients in the 14 days leading up to the first positive CRKP culture. Use of β-lactam/β-
lactamase inhibitors (22%) and fluoroquinolones (18%) were common as well. Prior use of 
tigecycline was uncommon, only 6% of patients had received tigecycline.
Tigecycline susceptibility
At the time of their index culture, 132/287 (46%, 95%CI 40%–52%) of patients presented 
with a tigecycline non-susceptible CRKP isolate. The distribution of MICs for tigecycline is 
shown in Figure 1. Using univariable analysis, origin prior to admission was strongly 
associated with tigecycline susceptibility (p<0.0001). Admission from a skilled nursing 
facility was then compared to all other points of origin prior to hospitalization in 
multivariable logistic regression analysis (Table 4). In contrast, admission from LTAC was 
not associated with tigecycline non-susceptibility (data not shown). In this model, admission 
from a skilled nursing facility (OR 2.51, 95% CI 1.51–4.21, p=0.0004), POA onset (OR 
1.82, 95% CI 1.06–3.15, p=0.03), and receipt of tigecycline within 14 days (OR 4.38, 95% 
CI 1.37–17.01, p=0.02) were found to be independent risk factors for tigecycline non-
susceptibility. An ordinal logistic regression model was also constructed for the ordinal 
outcome of tigecycline susceptibility (i.e. susceptible vs. intermediate vs. resistant). In this 
model, the same variables were also found to be associated with the ordinal outcome; 
admission from a skilled nursing facility (p=0.0005), POA onset (p=0.0064), and receipt of 
tigecycline within 14 days (p=0.0094). After stratification by CRKP infection vs. 
colonization, admission from a skilled nursing facility remained independently associated 
with tigecycline non-susceptibility in multivariable analysis (OR 3.61, 95% CI 1.59–8.53, 
p=0.002 in patients with CRKP infection, and OR 2.38, 95% CI 1.18–4.86, p=0.015 in 
patients with CRKP colonization).
Discussion
In this defined cohort, predictors of tigecycline non-susceptibility in patients with CRKP 
include: i) admission from a skilled nursing facility ii) having an early onset of positive 
culture within the hospital stay; and iii) receipt of tigecycline in the previous 14 days. When 
the impact of treatment of CRKP bacteriuria on the development of tigecycline resistance 
was previously evaluated, we found that tigecycline treatment of the index CRKP bacteriuria 
was strongly associated with risk for subsequent development of tigecycline resistance (OR 
6.13, 95%CI 1.15–48.65, p=0.03)7. In addition, this resistance was found to develop rapidly 
at a median of 65 days7. Nigo et al. evaluated the development of tigecycline resistance in 
multi-drug resistant K. pneumoniae (60% of these were CRKP) in a retrospective single-
center case-control study15. They also found that tigecycline exposure was associated with 
the subsequent development of tigecycline resistance (OR 5.06; 95% CI, 1.80 to 14.23; 
p=0.002)15. They did not evaluate origin prior to hospitalization.
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Patients admitted from a nursing home who had a positive culture on the first or second day 
of hospitalization were at the highest risk of having a tigecycline-non-susceptible CRKP 
isolate. This finding implies that these patients came in colonized with CRKP before their 
hospitalization. While we cannot establish in this study where the origin is of tigecycline-
non-susceptible CRKP, these findings are suggestive that either transmission of these 
isolates and/or de novo resistance mutations occur outside of the acute care setting.
In our cohort, the majority of patients with CRKP are older adults admitted from skilled 
nursing facilities. The presence of CRKP has been described in skilled nursing facilities 
outside of the US16,17. Within the US, CRKP has been isolated from patients transferred 
from LTACs and other LTCFs that provide mechanical ventilation, but recovery from 
patients transferred from skilled nursing facilities has been infrequently reported18,19. The 
findings from the current study suggest that CRKP might have disseminated throughout 
skilled nursing facilities to a greater degree than has been previously described.
The number of Americans living in nursing homes continues to increase and is currently 
estimated around 3 million people. The Centers for Disease Control and Prevention estimate 
that about 1 to 3 million serious infections occur in these patients annually, and that as many 
as 380,000 people die of these infections per year20. Most nursing home residents receive at 
least one course of antibiotics per year, and most courses exceed 7 days21,22. In addition, 
other risk factors for acquiring multi-drug resistant organisms are prevalent in this 
population as well, including frequent use of indwelling devices such as urinary catheters, 
chronic wounds, advanced age, and comorbidities23.
The findings presented here suggest that nursing homes should be an increasingly important 
area of research and implementation of preventative strategies including infection control 
and antimicrobial stewardship to curtail the spread of resistance to antibiotics of last resort 
in CRE. Currently, tigecycline, polymyxins such as colistin, and aminoglycosides given as 
monotherapy or in combination with carbapenems are believed to represent the cornerstone 
of treatment of CRE infections3,24. Novel agents including novel aminoglycosides such as 
plazomicin and various β-lactam/ β-lactamase inhibitor combinations are currently under 
study and will hopefully become available for widespread clinical use soon4,5. As the first of 
such agents, ceftazidime/avibactam was recently approved by the Food and Drug 
Administration (FDA). However, resistance to these agents will likely develop over time as 
well, and is likely to be related to similar risk factors23. Therefore, taking action to limit 
spread of tigecycline resistant isolates will likely limit resistance development to novel anti-
CRE antimicrobials as well. Worryingly, resistance to ceftazidime/avibactam has already 
been reported in Pseudomonas aeruginosa25
The main limitation of this study is that nursing homes are not part of CRaCKle. Rather, we 
are monitoring the impact of nursing homes by comprehensively monitoring all hospitalized 
patients with positive cultures for CRKP. Therefore, we are examining the “tip of the 
iceberg” and are missing those nursing home residents with rectal CRKP carriage, who are 
not admitted to the hospital or who have no clinical cultures positive for CRKP. Follow-up 
studies are needed that examine this issue directly in the nursing home. However, this multi-
center consortium covers the great majority of hospitals in the region and by employing a 
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comprehensive inclusion strategy, we have an unbiased cohort. In addition, these are the 
patients who confront acute care physicians. Another limitation of this study is that data on 
prior antibiotic usage was evaluated only for the 14-day period prior to the first positive 
CRKP culture. Only antibiotics reported either in notes or medication lists of the electronic 
medical record were included which may have led to an underestimation of antibiotic usage. 
However, in an independent cohort, tigecycline use also was the only antibacterial 
independently associated with tigecycline resistance15. This validates our finding that 
tigecycline use is a major driver of tigecycline resistance development. While this is 
intuitive, it is important to note that for other MDRO, a direct link is not always the main 
driver of resistance; for instance ceftriaxone use rather than vancomycin use was shown to 
be related to vancomycin resistance in Enterococcus faecium26. Finally, only patients with 
isolates that were clinically tested for tigecycline susceptibility were included, which may 
have resulted in an over-estimate of tigecycline non-susceptibility. However, the majority of 
CRKP isolates in CRACKLE are routinely tested for tigecycline susceptibility.
In summary, in this multi-center, prospective cohort of hospitalized patients with CRKP, 
patients with tigecycline non-susceptible isolates were found to be similar in most respects 
to patients with tigecycline susceptible CRKP. The three variables associated with decreased 
tigecycline susceptibility were previous tigecycline exposure, admission from a nursing 
home setting, and a positive culture for CRKP within the first 2 days of hospitalization. 
These findings emphasize the need for antimicrobial stewardship, as well as the urgent need 
for evaluation of optimal infection control practices in long term care.
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Tigecycline minimal inhibitory concentration (MIC) distribution in carbapenem-resistant 
Klebsiella pneumoniae isolates by origin prior to hospitalization.
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n 287 155 132
Age, median (IQR) 71 (59–81) 69 (57–79) 72 (63–83) 0.0512
Gender, Female 181 (63) 93 (60) 88 (67) 0.2703
Race 0.6346
 White 154 (54) 87 (56) 67 (51)
 Black 118 (41) 60 (39) 58 (44)
 Other 14 (5) 8 (5) 6 (5)
Charlson comorbidity index 3 (2–5) 3 (2–5) 4 (2–6) 0.0520
Diabetes mellitus 149 (52) 73 (47) 76 (58) 0.0969
Chronic kidney disease 65 (23) 36 (23) 29 (22) 0.8876
Malignancy 37 (13) 19 (12) 18 (14) 0.7281
Immunocompromised 27 (9) 18 (12) 9 (7) 0.2234
 Corticosteroids 13 (5) 5 (3) 8 (6) –
 Solid organ transplant 11 (4) 10 (6) 1 (1) –
 Hematopoietic stem cell transplant 2 (1) 2 (1) 0 –
 HIV infection 1 (0) 1 (1) 0 –
Origin <0.0001
 Skilled nursing facility 153 (53) 64 (41) 89 (67)
 Home 77 (27) 49 (32) 28 (21)
 Hospital transfer 37 (13) 30 (19) 7 (5)
 Long term acute care 20 (7) 12 (8) 8 (6)
All data in n (%), unless otherwise indicated. IQR: interquartile range





















n 287 155 132
Source 0.5238
 Urine 175 (61) 91 (59) 84 (64)
 Blood 39 (14) 26 (17) 13 (10)
 Wound 33 (11) 18 (11) 15 (11)
 Respiratory 31 (11) 16 (10) 15 (11)
 Other 9 (3) 4 (3) 5 (4)
Infection 127 (44) 74 (48) 53 (40) 0.2332
Critically ill at time of culturea 93 (32) 54 (35) 39 (30) 0.3767
Patient location at time of culture 0.3950
 Ward 119 (41) 69 (45) 50 (38)
 Intensive care unit 91 (32) 49 (32) 42 (32)
 Emergency department 77 (27) 37 (24) 40 (30)
Present on admissionb 184 (64) 89 (57) 95 (72) 0.0134
Hospital length of stay, days, median (IQR) 10 (6–18) 12 (7–23) 8 (5–14) 0.0015
All data in n (%), unless otherwise indicated.
a
as defined by Pitt bacteremia score≥4 on the day of first positive culture.
b
defined as a positive culture within within 48 hours of hospitalization. IQR: interquartile range
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n 287 155 132
Exposure to any antibiotic in 14 days prior to cultures 111 (39) 56 (36) 55 (42) 0.3947
 Tigecycline 16 (6) 4 (3) 12 (9) 0.0201
 Carbapenem 44 (15) 28 (18) 16 (12) 0.1899
 Fluoroquinolone 53 (18) 30 (19) 23 (17) 0.7607
 Colistin 3 (1) 2 (1) 1 (1) 1.000
 Vancomycin 87 (30) 47 (30) 40 (30) 1.000
 β-lactam/β-lactamase inhibitor 62 (22) 36 (23) 26 (20) 0.5651
 Cephalosporin 27 (9) 15 (10) 12 (9) 1.000
 Aminoglycoside 18 (6) 10 (6) 8 (6) 1.000
 Metronidazole 13 (5) 7 (5) 6 (5) 1.000
 Daptomycin 14 (5) 9 (6) 5 (4) 0.5844
 Other 76 (26) 48 (31) 28 (21) 0.0807
Number of classes of antibiotics 0.6796
 None 111 (39) 56 (36) 55 (42)
 One 52 (18) 28 (18) 24 (18)
 Two 58 (20) 35 (23) 24 (18)
 more than two 66 (23) 36 (23) 30 (23)
All data in n (%), unless otherwise indicated.
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Table 4
Risk factors for tigecycline non-susceptibility.
OR 95% CI p
Admission from skilled nursing facility 2.52 1.51–4.24 0.0004
Present on admission 1.77 1.03–3.08 0.038
Receipt of tigecycline within 14 days 4.41 1.36–17.24 0.012
Multivariable logistic regression model which also included age, Charlson score and presence of diabetes mellitus.
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